Punch: Preliminary results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).

Zongren Wang,Wenhao Zhan,Bin Huang,Cheng Luo,Lingwu Chen,Junxing Chen

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.618

IF: 45.3

2024-01-31

Journal of Clinical Oncology

Abstract:618 Background: Previous studies have proved IAC could reduce the recurrence and progression of HR NMIBC. The KEYNOTE-057 study has supported the benefits of PD-1 inhibitor in HR NMIBC patients (pts). Our study was established to evaluate the efficacy and safety of IAC combined with tislelizumab and BCG as a bladder-preserving treatment for HR NMIBC pts. Methods: This open-label, single arm phase II study enrolled BCG-naïve HR NMIBC pts with papillary tumors (high-grade Ta or T1 tumors). Firstly, the papillary tumors should be removed all visible lesions by transurethral resection of bladder tumor (TURBT). Secondly, angiographic catheter was placed into the internal iliac arteries with Seldinger’s percutaneous technique, cisplatin (60 mg/m 2 ) and epirubicin (50 mg/m 2 ) were administered arterially in day 1 (D1), every 3 weeks for 2-4 cycles. And pts received tislelizumab 200 mg IVGTT in D1, every 3 weeks for 2-4 cycles. Finally, pts received 18 instillations of BCG plus at least 8 cycles of tislelizumab (200 mg IVGTT, every 3 weeks). Specifically, pts were started on an induction course of BCG with 6 instillations every week, followed by maintenance with 3 instillations every 2 weeks and 9 instillations every 4 weeks. The primary end point was disease-free survival (DFS) rate at 12 months (defined as no reappearance of high grade or T1 tumors or clinical stage development after the therapy). Secondary end points were bladder-preservation rate, OS and safety. Our study estimated a DFS rate at 12 months was no less than 55% and the study would enroll 27 pts. Results: By Sep. 2023, 13 eligible pts were enrolled. Ten pts were analyzed (male 80.0%; median age 58 years (39-77); pure TCC 80.0%; median tumor size 2.5 cm (0.6-5.4); multiple papillary tumours=60.0%; high-grade Ta=40.0%, T1=60.0%). Median follow-up was 16.4 months (10.8-33.9), the mean number of IAC cycles was 2.4, mean number of tislelizumab cycles was 15.8, and the median BCG instillations was 16 (11-18). The DFS rate at 12 month was 90.0% (95%CI, 71.5%-98.6%). One pt showed reappearance of high-grade Ta and received TURBT. The bladder-preservation rate at 12 months was 100% (95%CI, 100%-100%). The OS rate at 12 months was 100% (95%CI, 100%-100%). 3 pts experienced treatment related adverse events, including nausea (n=1, G2), myalgia (n=1, G2), fatigue (n=1, G2), neutropenia (n=1, G2) and fever (n=1, G3). Conclusions: Our preliminary results supported the use of IAC combined with tislelizumab and BCG as a promising bladder-preserving strategy for HR NMIBC pts. Clinical trial information: ChiCTR2200067146 .

oncology